137 related articles for article (PubMed ID: 10222833)
1. ["Prostatic" kallikreins, sex hormones and insulin-like growth factors: complex of male and female regulatory elements in health and carcinogenesis].
Zezerov EG; Severin ES
Vestn Ross Akad Med Nauk; 1999; (3):49-56. PubMed ID: 10222833
[TBL] [Abstract][Full Text] [Related]
2. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer.
Miyata Y; Sakai H; Hayashi T; Kanetake H
Prostate; 2003 Feb; 54(2):125-32. PubMed ID: 12497585
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer.
Khosravi J; Diamandi A; Mistry J; Scorilas A
J Clin Endocrinol Metab; 2001 Feb; 86(2):694-9. PubMed ID: 11158033
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen enhances bioavailability of insulin-like growth factor by degrading insulin-like growth factor binding protein 5.
Maeda H; Yonou H; Yano K; Ishii G; Saito S; Ochiai A
Biochem Biophys Res Commun; 2009 Apr; 381(3):311-6. PubMed ID: 19250630
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen and human glandular kallikrein: two kallikreins of the human prostate.
Henttu P; Vihko P
Ann Med; 1994 Jun; 26(3):157-64. PubMed ID: 7521173
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma.
Cohen P; Graves HC; Peehl DM; Kamarei M; Giudice LC; Rosenfeld RG
J Clin Endocrinol Metab; 1992 Oct; 75(4):1046-53. PubMed ID: 1383255
[TBL] [Abstract][Full Text] [Related]
9. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
Arnold JT; Le H; McFann KK; Blackman MR
Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E573-84. PubMed ID: 15536203
[TBL] [Abstract][Full Text] [Related]
10. Ovarian follicular concentrations of activin, follistatin, inhibin, insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-2 (IGFBP-2), IGFBP-3, and vascular endothelial growth factor in spontaneous menstrual cycles of normal women of advanced reproductive age.
Klein NA; Battaglia DE; Woodruff TK; Padmanabhan V; Giudice LC; Bremner WJ; Soules MR
J Clin Endocrinol Metab; 2000 Dec; 85(12):4520-5. PubMed ID: 11134102
[TBL] [Abstract][Full Text] [Related]
11. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells.
Veveris-Lowe TL; Lawrence MG; Collard RL; Bui L; Herington AC; Nicol DL; Clements JA
Endocr Relat Cancer; 2005 Sep; 12(3):631-43. PubMed ID: 16172196
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and prostate cancer: correlation with Gleason score.
Correa LL; Neto LV; Lima GA; Gabrich R; Miranda LC; Gadelha MR
Int Braz J Urol; 2015; 41(1):110-5. PubMed ID: 25928516
[TBL] [Abstract][Full Text] [Related]
13. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
Scorilas A; Plebani M; Mazza S; Basso D; Soosaipillai AR; Katsaros N; Pagano F; Diamandis EP
Prostate; 2003 Feb; 54(3):220-9. PubMed ID: 12518327
[TBL] [Abstract][Full Text] [Related]
14. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
Oliver SE; Holly J; Peters TJ; Donovan J; Persad R; Gillatt D; Pearce A; Hamdy FC; Neal DE; Gunnell D
Urology; 2004 Aug; 64(2):317-22. PubMed ID: 15302487
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen and other prostate-derived proteases cleave IGFBP-3, but prostate cancer is not associated with proteolytically cleaved circulating IGFBP-3.
Koistinen H; Paju A; Koistinen R; Finne P; Lövgren J; Wu P; Seppälä M; Stenman UH
Prostate; 2002 Feb; 50(2):112-8. PubMed ID: 11816019
[TBL] [Abstract][Full Text] [Related]
16. Changes of PSA concentrations in serum and saliva of healthy women during the menstrual cycle.
Aksoy H; Akçay F; Umudum Z; Yildirim AK; Memisogullari R
Ann Clin Lab Sci; 2002; 32(1):31-6. PubMed ID: 11848615
[TBL] [Abstract][Full Text] [Related]
17. Serum insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia.
Aksoy Y; Aksoy H; Bakan E; Atmaca AF; Akçay F
Urol Int; 2004; 72(1):62-5. PubMed ID: 14730168
[TBL] [Abstract][Full Text] [Related]
18. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era.
Platz EA; Pollak MN; Leitzmann MF; Stampfer MJ; Willett WC; Giovannucci E
Cancer Causes Control; 2005 Apr; 16(3):255-62. PubMed ID: 15947877
[TBL] [Abstract][Full Text] [Related]
19. Characterization of prostate-specific antigen proteolytic activity on its major physiological substrate, the sperm motility inhibitor precursor/semenogelin I.
Robert M; Gibbs BF; Jacobson E; Gagnon C
Biochemistry; 1997 Apr; 36(13):3811-9. PubMed ID: 9092810
[TBL] [Abstract][Full Text] [Related]
20. Association of kallikrein expression in nipple aspirate fluid with breast cancer risk.
Sauter ER; Lininger J; Magklara A; Hewett JE; Diamandis EP
Int J Cancer; 2004 Feb; 108(4):588-91. PubMed ID: 14696124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
